---
schema_version: "secwatch.filing_event.v1"
accession: "0001096906-26-001112"
form_type: "8-K"
ticker: "UTMD"
cik: "0000706698"
company_name: "UTAH MEDICAL PRODUCTS INC"
filed_at: "2026-07-23T19:13:28+00:00"
generated_at: "2026-07-23T19:14:11.545428+00:00"
event_type: "earnings"
sentiment: "negative"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# UTMD Q2 2026 revenue down 14.3% to $8.5M; EPS $0.844 vs $0.939; cuts FY2026 guidance to -10-13% decline

## Summary
- Q2 2026 revenue $8.53M, down 14.3% from $9.95M in Q2 2025; 1H revenue $17.25M, down 12.3%.
- Diluted EPS $0.844 in Q2 2026 vs $0.939 in Q2 2025, a 10.1% decline; 1H EPS $1.661 vs $1.858.
- FY2026 revenue guidance cut to decline of 10-13% from prior expectation of flat; new product sales slower than expected.
- Litigation costs in 1H 2026 were $1.3M vs $1.0M in 1H 2025; now expects 2026 litigation <$1.6M vs prior <$1.355M.
- Cash and investments $87.5M, no debt; share repurchases minimal at $0.2M in 1H 2026 vs $6.7M in 1H 2025.

## SEC filing metadata
- accession: 0001096906-26-001112
- form_type: 8-K
- ticker: UTMD
- cik: 0000706698
- company_name: UTAH MEDICAL PRODUCTS INC
- filed_at: 2026-07-23T19:13:28+00:00
- event_type: earnings
- sentiment: negative
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01, 99.1
- EDGAR index: https://www.sec.gov/Archives/edgar/data/706698/000109690626001112/0001096906-26-001112-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/706698/000109690626001112/utmd-20260723_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001096906-26-001112
- JSON: https://secwatch.observer/filing/0001096906-26-001112.json
- Plain text: https://secwatch.observer/filing/0001096906-26-001112.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.